Tokyo, Japan—Tosoh launched in November 2013 worldwide sales of its newly developed separation media Toyopearl AF-r Protein A HC-650F. Production is taking place at its Nanyo Complex in Yamaguchi Prefecture, Japan. Toyopearl AF-r Protein A HC-650F will meet a crucial need within the biopharmaceutical industry.
The biopharmaceutical industry is growing rapidly in Japan, in the United States, in the countries of Europe, and in China, India and other developing nations. And Protein A–affinity separation media is indispensable to the industry’s purification of monoclonal antibodies in the production of antibody biopharmaceuticals. The industry, therefore, is certain to welcome the arrival of Tosoh’s new Protein A–affinity separation media, which exhibits high binding affinity, alkaline resistance, and mechanical stability.
Toyopearl AF-r Protein A HC-650F is a high-performance separation media that achieves 30% to 50% greater antibody adsorption than similar products. That represents binding capacity of approximately 70 grams of antibody volume per liter of separation media. Even when Toyopearl AF-r Protein A HC-650F is used on high titer samples, its high adsorption ensures quality antibodies. Higher binding capacity and alkaline resistance of media supports a significant decrease in production and operational costs. Similarly, the high mechanical stability that the product features as a result of its structure of hard resins support rapid antibody purification.
Toyopearl AF-r Protein A HC-650F, which is also available in ToyoScreen mini-size columns for screening and evaluation, is the latest addition to Tosoh’s extensive lineup of separation media ideally suited to antibody purification in the development and manufacture of antibody biopharmaceuticals. Tosoh will continue to strengthen that and other of Tosoh’s biopharmaceutical-related product lineups to better serve the development of cutting-edge biopharmaceuticals. Antibody biopharmaceuticals have received the most public attention because they display high therapeutic efficiency, are used in the treatment of such life-threatening diseases as cancer, and are the biotechnology-based pharmaceuticals being developed at the fastest rate.
Tosoh’s Bioscience Division
Tosoh’s Bioscience Division is expanding globally in three markets: separations, clinical diagnostics, and genetic testing. Its separation product lines include high-performance liquid chromatography (HPLC) systems and columns and separation media. Its offerings for the clinical diagnostic market center on HPLC and automated immunoassay (AIA) analyzers and reagents. Tosoh’s genetic testing products include diagnostic equipment furnishing real-time amplification and detection of ribonucleic acid (RNA).
| TOSOH CORPORATION |
| |
| WHO WE ARE |
| Tosoh Corporation is a Japanese chemical company established in 1935 and listed on the First Section of the Tokyo Stock Exchange. It is the parent of the Tosoh Group, which comprises 140 companies worldwide and a multiethnic workforce of over 11,000 people and generated net sales of ¥668.5 billion (US$7.1 billion at the year-end rate of ¥94.05 to the US dollar) in fiscal 2013, ended March 31, 2013. |
|
| WHAT WE DO |
| Tosoh is one of the largest chlor-alkali manufacturers in Asia. The Company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh's petrochemical operations supply ethylene, polymers, and polyethylene, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases, such as diabetes and certain cancers, and to prevent epidemics by identifying pathogenic microbes. In addition, as part of a commitment to a sustainable future, Tosoh manufacturers a variety of eco-products such as the company’s emission-free polyurethane catalyst. |
|
| Stock Exchange Ticker Symbol: 4042 |
|
| DISCLAIMER |
| This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. The forward-looking statements are also identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. |